Jürgen Steffgen

870 total citations
25 papers, 639 citations indexed

About

Jürgen Steffgen is a scholar working on Molecular Biology, Radiology, Nuclear Medicine and Imaging and Immunology. According to data from OpenAlex, Jürgen Steffgen has authored 25 papers receiving a total of 639 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 7 papers in Radiology, Nuclear Medicine and Imaging and 7 papers in Immunology. Recurrent topics in Jürgen Steffgen's work include Monoclonal and Polyclonal Antibodies Research (7 papers), Ion Transport and Channel Regulation (6 papers) and Drug Transport and Resistance Mechanisms (5 papers). Jürgen Steffgen is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (7 papers), Ion Transport and Channel Regulation (6 papers) and Drug Transport and Resistance Mechanisms (5 papers). Jürgen Steffgen collaborates with scholars based in Germany, United States and France. Jürgen Steffgen's co-authors include Gerhard Burckhardt, Birgitta C. Burckhardt, Gerhard A. Müller, Sudha Visvanathan, Jay S. Fine, Meera Ramanujam, Karel Geboes, Thomas Knittel, Geert D’Haens and Jean‐Frédéric Colombel and has published in prestigious journals such as Journal of Biological Chemistry, SHILAP Revista de lepidopterología and Antimicrobial Agents and Chemotherapy.

In The Last Decade

Jürgen Steffgen

25 papers receiving 626 citations

Peers

Countries citing papers authored by Jürgen Steffgen

Since Specialization

Citations

This map shows the geographic impact of Jürgen Steffgen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jürgen Steffgen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jürgen Steffgen more than expected).

Fields of papers citing papers by Jürgen Steffgen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jürgen Steffgen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jürgen Steffgen. The network helps show where Jürgen Steffgen may publish in the future.

Co-authorship network of co-authors of Jürgen Steffgen

This figure shows the co-authorship network connecting the top 25 collaborators of Jürgen Steffgen. A scholar is included among the top collaborators of Jürgen Steffgen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jürgen Steffgen. Jürgen Steffgen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Two-year treatment experience with BI 655064, an antagonistic anti-CD40 antibody, in patients with active lupus nephritis: An exploratory, phase II maintenance trial 2025 ·Lupus ·Richard Furie, Jürgen Steffgen, Nora Fagan, Juanita Romero‐Díaz, Yingyos Avihingsanon, Dimitrios T. Boumpas, Kajohnsak Noppakun, Jing Wu, (unknown), David Jayne	1
2	Clinical and Biomarker Responses to BI 655064, an Antagonistic Anti‐CD40 Antibody, in Patients With Active Lupus Nephritis: A Randomized, Double‐Blind, Placebo‐Controlled, Phase II Trial 2023 ·Arthritis & Rheumatology ·David Jayne, Jürgen Steffgen, Juanita Romero‐Díaz, Ingeborg M. Bajema, Dimitrios T. Boumpas, Kajohnsak Noppakun, Hirofumi Amano, (unknown), Bancha Satirapoj, Yingyos Avihingsanon, (unknown), Magdalena Madero, Beata Naumnik, (unknown), Nora Fagan, (unknown), Jing Wu, Sudha Visvanathan, Richard Furie	13
3	Phoenix from the flames: Rediscovering the role of the CD40–CD40L pathway in systemic lupus erythematosus and lupus nephritis 2020 ·Autoimmunity Reviews ·Meera Ramanujam, Jürgen Steffgen, Sudha Visvanathan, Chandra Mohan, Jay S. Fine, Chaim Putterman	52
4	Safety, pharmacokinetics and pharmacodynamics of BI 655064 in phase 1 clinical trials in healthy Chinese and Japanese subjects 2020 ·British Journal of Clinical Pharmacology ·Yasuhiro Tsuda, Christine Grimaldi, Fenglei Huang, (unknown), (unknown), Steven J. Padula, In‐Jin Jang, Jürgen Steffgen	4
5	Safety, pharmacokinetics and pharmacodynamics of BI 705564, a highly selective, covalent inhibitor of Bruton's tyrosine kinase, in Phase I clinical trials in healthy volunteers 2020 ·British Journal of Clinical Pharmacology ·Tobias Litzenburger, Jürgen Steffgen, (unknown), Fabian Müller, Armin Schultz, Elliott Klein, Meera Ramanujam, Christian Harcken, (unknown), Jing Wu, Sabrina Wiebe, Xiujiang Li, Mary Flack, Steven J. Padula, Sudha Visvanathan, (unknown), Jianan Hui	4
6	Effects of BI 655064, an antagonistic anti-CD40 antibody, on clinical and biomarker variables in patients with active rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase IIa study 2019 ·Annals of the Rheumatic Diseases ·Sudha Visvanathan, (unknown), (unknown), Ulf Müller‐Ladner, Meera Ramanujam, (unknown), Anastasia G Eleftheraki, Richard Vinisko, (unknown), Herbert Kellner, Eva Dokoupilová, Brygida Kwiatkowska, Rieke Alten, Christian Schwabe, Patrick Baum, David Joseph, Jay S. Fine, Steven J. Padula, Jürgen Steffgen	44
7	32 Safety, pharmacokinetics and pharmacodynamics of BI 705564, a covalent inhibitor of brutons tyrosine kinase in phase 1 clinical trials in healthy volunteers 2019 ·Abstracts ·Tobias Litzenburger, Fabian Müller, Armin Schultz, Elliott Klein, Meera Ramanujam, Jing Wu, Sabrina Wiebe, (unknown), Jianan Hui, Xiujiang Li, Mary Flack, Steven J. Padula, Sudha Visvanathan, Jürgen Steffgen, (unknown)	1
8	Safety, pharmacokinetics and pharmacodynamics of single rising doses of BI 655064, an antagonistic anti-CD40 antibody in healthy subjects: a potential novel treatment for autoimmune diseases 2017 ·European Journal of Clinical Pharmacology ·(unknown), Frank Wagner, Andreas Hüser, (unknown), David Joseph, James Hilbert, Corinna Schoelch, Steven J. Padula, Jürgen Steffgen	30
9	Functional roles of cationic amino acid residues in the sodium-dicarboxylate cotransporter 3 (NaDC-3) from winter flounder 2006 ·American Journal of Physiology-Renal Physiology ·Yohannes Hagos, Jürgen Steffgen, Ahsan Rizwan, (unknown), (unknown), Gerhard Burckhardt, Birgitta C. Burckhardt	7
10	Oral p38 Mitogen-Activated Protein Kinase Inhibition With BIRB 796 for Active Crohn’s Disease: A Randomized, Double-Blind, Placebo-Controlled Trial 2006 ·Clinical Gastroenterology and Hepatology ·Stefan Schreiber, Brian G. Feagan, Geert D’Haens, Jean‐Frédéric Colombel, Karel Geboes, (unknown), Isakov Va, О. В. Головенко, Çharles N. Bernstein, D Ludwig, Trevor A. Winter, Ulrich Meier, (unknown), Jürgen Steffgen	146
11	Presence of organic anion transporters 3 (OAT3) and 4 (OAT4) in human adrenocortical cells 2004 ·Pflügers Archiv - European Journal of Physiology ·Abdul R. Asif, Jürgen Steffgen, (unknown), R. Willi Grunewald, Gerhard A. Müller, Andrew Bahn, Gerhard Burckhardt, Yohannes Hagos	39
12	Regulation of sodium-dicarboxylate cotransporter-3 from winter flounder kidney by protein kinase C 2004 ·American Journal of Physiology-Renal Physiology ·Yohannes Hagos, Birgitta C. Burckhardt, (unknown), Christian Mathys, (unknown), Andrew Bahn, Natascha A. Wolff, Gerhard Burckhardt, Jürgen Steffgen	17
13	Interactions of Benzylpenicillin and Non-steroidal Anti-inflammatory Drugs with the Sodium-dependent Dicarboxylate Transporter NaDC-3 2004 ·Cellular Physiology and Biochemistry ·Birgitta C. Burckhardt, (unknown), Gerhard Burckhardt, Jürgen Steffgen	12
14	Basolateral localization of flounder Na+-dicarboxylate cotransporter (fNaDC-3) in the kidney of Pleuronectes americanus 2003 ·Pflügers Archiv - European Journal of Physiology ·Hartmut Hentschel, Birgitta C. Burckhardt, Beate Schölermann, (unknown), Gerhard Burckhardt, Jürgen Steffgen	11
15	Expression of reelin in hepatic stellate cells and during hepatic tissue repair: a novel marker for the differentiation of HSC from other liver myofibroblasts 2002 ·Journal of Hepatology ·Dominik Kobold, (unknown), Fabio Piscaglia, Christoph Eisenbach, Katrin Neubauer, Jürgen Steffgen, Giuliano Ramadori, Thomas Knittel	78
16	Potential-dependent steady-state kinetics of a dicarboxylate transporter cloned from winter flounder kidney 2000 ·Pflügers Archiv - European Journal of Physiology ·Birgitta C. Burckhardt, Jürgen Steffgen, (unknown), Gerhard A. Müller, Gerhard Burckhardt	7
17	Expression Cloning and Characterization of a Novel Sodium-Dicarboxylate Cotransporter from Winter Flounder Kidney 1999 ·Journal of Biological Chemistry ·Jürgen Steffgen, Birgitta C. Burckhardt, Christoph Langenberg, (unknown), Gerhard A. Müller, Gerhard Burckhardt, Natascha A. Wolff	32
18	Demonstration of a Probenecid-Inhibitable Anion Exchanger Involved in the Release of Cortisol and cAMP and in the Uptake of <i>p</i>-Aminohippurate in Bovine Adrenocortical Cells 1999 ·Cellular Physiology and Biochemistry ·Jürgen Steffgen, Saskia Rohrbach, (unknown), (unknown), Hubertus Jarry, (unknown), Stefan R. Bornstein, Gerhard A. Müller, Gerhard Burckhardt	11
19	Highly Specific Separation of Heterogeneous Cell Populations by Lectin-Coated Beads: Application for the Isolation of Inner Medullary Collecting Duct Cells 1998 ·Nephron Experimental Nephrology ·Clemens Grupp, (unknown), Jürgen Steffgen, Sigrid A. Langhans, David I. Cohen, Lydia Brandl, Gerhard A. Müller	14
20	Characterization of p-aminohippurate transport from rat kidney which is expressed after injection of size-selected mRNA into oocytes of Xenopus laevis 1993 ·Biochimica et Biophysica Acta (BBA) - Biomembranes ·Jürgen Steffgen, (unknown), Dirk Gründemann, (unknown), (unknown), Hermann Koepsell	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact